Skip to main content

Table 5 Seroprotective rates and GMTs for anti-HBs antibodies from Months 0 to 20 (ATP Cohort for Immunogenicity)

From: Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02D malaria vaccine in infants living in a malaria-endemic region

Group

Timing

N

Seroprotected

GMT (mIU/mL)

   

n

%

95% CI

 

Value

95% CI

 

RTS,S/AS02D

SCREENING

115

44

38.3

29.4

47.8

14.5

10.9

19.2

 

Post Dose 2 (Month 2)

148

140

94.6

89.6

97.6

110.9

89.1

138.1

 

Post Dose 3 (Month 3)

140

140

100

97.4

100

667.3

532.9

835.7

 

Post Dose 3 (Month 20)

131

131

100

97.2

100

1520.6

1206.8

1915.8

Hepatitis B

SCREENING

131

45

34.4

26.3

43.1

13.3

10.0

17.6

vaccine

Post Dose 2 (Month 2)

147

82

55.8

47.4

64.0

17.1

13.6

21.4

 

Post Dose 3 (Month 3)

141

133

94.3

89.1

97.5

113.8

91.3

141.8

 

Post Dose 3 (Month 20)

132

129

97.7

93.5

99.5

184.3

144.4

235.4

  1. Seroprotected ≥ 10 mIU/mL.
  2. N = number of subjects with available results.
  3. n/% = number/percentage of subjects with titre within the specified range.